The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

@article{Weberpals2009TheDR,
  title={The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer},
  author={Johanne I Weberpals and Kyla D Garbuio and Anna O'Brien and Katherine V. Clark-Knowles and Steve Doucette and Olga Antoniouk and Glenwood D Goss and Jim Dimitroulakos},
  journal={International Journal of Cancer},
  year={2009},
  volume={124}
}
This study compares Breast Cancer 1 (BRCA1) and excision repair cross complementation group 1 (ERCC1) expression as predictive markers and evaluates the in vitro enhancement of platinum sensitivity using targeted agents in sporadic ovarian cancer (OC). A retrospective study was performed of advanced stage OC patients receiving platinum‐based chemotherapy. BRCA1 and ERCC1 mRNA expression was determined from frozen tissue of 51 patients. Median overall survival (OS) was longer for patients with… 
The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
TLDR
Evidence is provided for a major role for BRCA1 mRNA expression as a marker of time to progression and overall survival in sporadic breast cancers treated with anthracycline-based chemotherapy.
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
TLDR
This study suggests that BRCA1 protein is a prognostic marker in sporadic OC patients with minimal RD and further research is needed to evaluate BRCa1 as a predictive biomarker and to target BRC a1 expression to enhance chemotherapeutic sensitivity.
Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
TLDR
BRCA1 protein expression is a feature of more proliferative and more aneuploid prostate tumors and is more common in metastatic disease and may be most relevant in advanced disease.
mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
TLDR
Survition in patients receiving second-line docetaxel-based chemotherapy showed a similar trend with PIAS1 and PIAS4 mRNA expression levels, although the associations for PIas4 were not statistically significant.
Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas
TLDR
This study shows for the first time that FANCD2 overexpression is a strong negative prognostic factor in ovarian cancer, particularly in patients treated with taxane-platinum (TP) or platinum-cyclophosphamide (PC) treatment.
Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer.
TLDR
It is demonstrated that positive ERCC1 expression is not associated with clinical resistance to platinum-based chemotherapy, ER CC1, AR& ER expression are not independent factors affecting the prognosis of patients with epithelial ovarian tumors and not related with survival benefits.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy
TLDR
Evidence is provided that inhibition of endogenous BRCA1 expression in ovarian cancer cell lines results in increased sensitivity to platinum therapy and decreased sensitivity to antimicrotubule agents and provides evidence to support a role for BRCa1 mRNA expression as a predictive marker of survival in sporadic epithelial ovarian cancer.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
TLDR
BRCA1 expression is potentially an important tool for use in cancer management and should be assessed for predicting differential chemosensitivity and tailoring chemotherapy in lung cancer.
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study
TLDR
Findings confirm a high rate of loss of BRCA1 protein expression in sporadic OEC and suggest a role of BrcA1 in the progression of sporadic ovarian carcinoma.
Prognostic significance of BRCA1 expression in sporadic breast carcinomas
TLDR
Loss of BRCA1 expression associated with high‐grade breast tumours suggests that BRCa1 may play an important role in the pathogenesis of sporadic breast cancer.
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.
TLDR
It is postulate that an intact DNA repair mechanism may reduce the accumulation of genetic aberrations that are thought to contribute to a tumors malignant potential and therefore the risk of relapse after definitive treatment.
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
TLDR
The findings suggest a specific chemosensitivity profile of BRCA1-defective cells in vitro, which is dependent on B RCA1 protein expression, and suggest prospective preclinical and clinical investigation for the development of tailored therapeutical approaches in this setting.
ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.
TLDR
ERCC1 expression levels in human tumor tissue may have a role in clinical resistance to platinum compounds, and these data appear to be consistent with the assertion that ERCC1 serves as an excision nuclease, whereas ERCC2 serves as a helicase.
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions
TLDR
It is clear that BRCA1 has significant roles in multiple fundamental cellular processes, including control of gene expression, chromatin remodeling, DNA repair, cell cycle checkpoint control, and ubiquitination, and overall is important for maintenance of genomic stability.
BRCA1 Regulates Gene Expression for Orderly Mitotic Progression
TLDR
It is suggested that BRCA1 transcriptionally regulates gene expression for orderly mitotic progession through down-regulation of genes involved in cell cycle regulation and in DNA replication and repair.
...
1
2
3
4
5
...